Patents by Inventor Luc Friboulet

Luc Friboulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
    Patent number: 9702875
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 11, 2017
    Assignee: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140170659
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet
  • EXPRESSION OF ISOFORM 202 OF ERCC1 FOR PREDICTING RESPONSE TO CANCER CHEMOTHERAPY
    Publication number: 20140120543
    Abstract: An in vitro method for detecting the susceptibility of a tumor cell to a chemotherapy is disclosed. The method includes the step of measuring the expression level of the isoform 202 of the ERCC1 protein.
    Type: Application
    Filed: September 9, 2013
    Publication date: May 1, 2014
    Applicant: INSTITUTE GUSTAVE-ROUSSY
    Inventors: Ken Olaussen, Jean-Charles Soria, Luc Friboulet